Top 30 Indonesian Antiseptic Public Companies Q3 2025 Revenue & Performance

1) Overall companies performance (Q3 2025 snapshot)
PT Jayamas Medica Industri Tbk
PT Kalbe Farma Tbk
PT Tempo Scan Pacific Tbk
PT Enseval Putera Megatrading Tbk
PT Siloam International Hospitals Tbk
PT Mitra Keluarga Karyasehat Tbk
PT Industri Jamu & Farmasi Sido Muncul Tbk
PT Darya-Varia Laboratoria Tbk
PT Kimia Farma Tbk
PT Indofarma Tbk
PT Medikaloka Hermina Tbk
PT Soho Global Health Tbk
PT Pyridam Farma Tbk
PT Ikapharmindo Putramas Tbk
PT Penta Valent Tbk
PT Metro Healthcare Indonesia Tbk
PT Sarana Meditama Metropolitan Tbk
PT Royal Prima Tbk
PT Millennium Pharmacon International Tbk
PT Medela Potentia Tbk
PT Sejahteraraya Anugrahjaya Tbk
PT Murni Sadar Tbk
PT Charlie Hospital Semarang Tbk
PT Uni-Charm Indonesia Tbk
PT Mustika Ratu Tbk
PT Victoria Care Indonesia Tbk
PT Akasha Wira International Tbk
PT Mandom Indonesia Tbk
PT Kino Indonesia Tbk
PT Martina Berto Tbk
2) Revenue results of major public companies in Indonesia summarized (per company)
PT Jayamas Medica Industri Tbk (OMED) - 9M 2025 Revenue: IDR 1.47 trillion (USD 88.1 million) 9M Net Profit: IDR 254.2 billion (USD 15.2 million) Steady growth driven by clinical and antiseptic product demand, especially wound care and antiseptic/dialysis fluids. Gross profit and EBITDA margins improved YoY.
PT Kalbe Farma Tbk (KLBF) - 9M 2025 Net Profit: IDR 2.63 trillion (USD 157.6 million) Core pharmaceutical and OTC hygiene products supported solid profits; antiseptic segments within consumer health contributed to revenue diversification.
PT Tempo Scan Pacific Tbk (TSPC) - 9M 2025 Net Profit: IDR 1.14 trillion (USD 68.3 million) Stable OTC and antiseptic/hygiene related sales maintain profitability amid modest demand variations.
PT Enseval Putera Megatrading Tbk (ENVA/EPMT) - 9M 2025 Net Profit: IDR 603.4 billion (USD 36.2 million) Distribution of clinical supplies and hygiene product kits lifted volume growth +5% YoY.
PT Siloam International Hospitals Tbk (SILO) - Q3 2025 Net Profit: IDR 761.3 billion (USD 45.6 million) Antiseptic usage remained robust in hospital environments with elective procedures and cleanliness protocols adding to revenue stability.
PT Mitra Keluarga Karyasehat Tbk (MIKA) - 9M 2025 PATMI: IDR 1.0 trillion (USD 59.9 million) Strong clinical services mix aided demand for antiseptic clinical products within hospital and outpatient settings.
PT Industri Jamu & Farmasi Sido Muncul Tbk (SIDO) - 9M 2025 Net Profit: IDR 818.5 billion (USD 49.0 million) Consumer health hygiene and OTC antiseptic formulations contributed to sequential sales growth.
PT Darya-Varia Laboratoria Tbk (DVLA) - Q3 2025 Net Profit: IDR 164.3 billion (USD 9.8 million) Core pharmaceuticals with adjunct antiseptic OTC lines.
PT Kimia Farma Tbk (KAEF) - 9M 2025 Net Loss: IDR 179.7 billion (USD 10.8 million) Although broad pharma operations weighed on earnings, continued focus on hygiene and OTC segments helped narrow the loss vs. prior periods.
PT Indofarma Tbk (INAF) - 9M 2025 Net Loss: IDR 127.1 billion (USD 7.6 million) Loss attributable to turnaround phase; antiseptic and clinical hygiene lines contributed to revenue base but margins remained under pressure.
3) Key trends & insights from Q3 2025
Stable Demand for Antiseptic & Hygiene Products - Healthcare providers and distributors noted consistent utilization of antiseptic solutions in clinical settings and home healthcare kits, underpinning revenue resilience.
Diversified Portfolios Bolstered Resilience - Firms with broader OTC and consumer healthcare segments (e.g., Kalbe, Tempo Scan) were better positioned to offset operational pressures in pure clinical supply segments.
Hospital Volume Recovery Boosts Clinical Sales - Hospitals (e.g., Siloam, Mitra Keluarga) experienced improved occupancy, translating to increased usage of antiseptic surgical and diagnostic supplies.
Distribution Channels Strengthened Access - Distributors like Enseval expanded clinical and hygiene product reach, moderating cost pressures and capturing volume growth +5%.
4) Outlook for Q4 2025 and beyond
Continued Healthcare Rebound - With elective procedures normalizing and preventive care demand steady, antiseptic and disinfectant product lines are expected to see continued uptake into Q4 2025.
Expansion of Hygiene Awareness - Consumer awareness around hygiene and infection control remains elevated, fuelling OTC antiseptic and disinfectant sales through retail and institutional channels.
Operational Efficiency & Margin Focus - Anticipated cost controls, supply chain improvements, and product mix optimization should support margin expansion for diversified players, particularly those able to adapt distribution and portfolio strategies.
Financial Discipline amid Macro Pressures - Pharmaceutical and healthcare firms facing macro volatility (e.g., Kimia Farma, Indofarma) may continue restructuring to return to profitability while maintaining critical antiseptic product availability.
5) Conclusion
The Indonesian antiseptic industry in Q3 2025 demonstrated stable demand dynamics and financial resilience, particularly among diversified healthcare and medical supply firms. Top performers like PT Jayamas Medica Industri, PT Kalbe Farma, and PT Tempo Scan Pacific showed meaningful profits driven by antiseptic, clinical hygiene, and related products. Hospital networks and distributors contributed to volume growth, while broader macroeconomic conditions encouraged operational discipline. Looking ahead, Q4 2025 is poised for continued growth in antiseptic demand across both clinical and consumer channels, underpinned by robust healthcare utilization and public hygiene awareness.

Contact Information:
Tel: +1 626 2952 442 (US) ; +86-1082945717 (China)
+62 896 3769 3166 (Whatsapp)
Email: willyanto@qyresearch.com; global@qyresearch.com
Website: www.qyresearch.com

About QY Research
QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.
Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.
We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.
More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.

This release was published on openPR.